Several metalloporphyrin inhibitors of HO activity are already in clinical use for the control of neonatal hyperbilirubinemia (jaundice) and certain adult liver conditions and, if secondary (‘bystander’) effects are successfully mitigated, could be adapted for the treatment of PD. The gene discussed is HMOX1; the disease is Jaundice.